What does CUSIP 05338F306 represent in this 13F holders report?

CUSIP 05338F306 is the security identifier for AVTX - Avalo Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held AVTX - Avalo Therapeutics, Inc. - Common Stock in Q3 2024?

28 institutional investors reported AVTX - Avalo Therapeutics, Inc. - Common Stock for Q3 2024. Use the holders table for investor-level position and value details.

Avalo Therapeutics, Inc. - Common Stock (AVTX)

CUSIP: 05338F306

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class: Equity / Common Stock
Shares outstanding: 52,343,750
Total 13F shares: 6,656,933
Share change: +5,885,831
Total reported value: $63,199,568
Price per share: $9.50
Number of holders: 28
Value change: +$55,874,127
Number of buys: 12
Number of sells: 3

Quarterly Holders Quick Answers

What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2024
Previous quarter: Q2 2024

Recent filing periods for CUSIP 05338F306:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AVTX - Avalo Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Logos Global Management LP	13F	Company	1%	539,079	$6,722,315	—	30 Jun 2024	13F
Sio Capital Management, LLC	13F	Company	0.14%	71,458	$891,081	—	30 Jun 2024	13F
Ikarian Capital, LLC	13F	Company	0.1%	54,730	$682,483	—	30 Jun 2024	13F
Affinity Asset Advisors, LLC	13F	Company	0.09%	45,000	$561,150	—	30 Jun 2024	13F
Commodore Capital LP	13F	Company	0.08%	40,000	$498,800	—	30 Jun 2024	13F
ARMISTICE CAPITAL, LLC	3/4/5	10%+ Owner	— class O/S missing	765,828	$397,771	—	26 Jun 2023	3/4/5
VANGUARD GROUP INC	13F	Company	0.02%	10,368	$129,289	—	30 Jun 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	5,601	$69,844	—	30 Jun 2024	13F
UBS Group AG	13F	Company	0.01%	3,583	$44,680	—	30 Jun 2024	13F
James Archie Harrell Jr.	3/4/5	Chief Commercial Officer	— class O/S missing	36,766	$19,096	—	10 Dec 2021	3/4/5
H. Jeffrey Wilkins	3/4/5	Chief Medical Officer	— class O/S missing	33,373	$17,334	—	10 Dec 2021	3/4/5
ROYAL BANK OF CANADA	13F	Company	0%	590	$7,000	—	30 Jun 2024	13F
BlackRock Finance, Inc.	13F	Company	0%	329	$4,103	—	30 Jun 2024	13F
Cantonale Vaudoise Banque	13F	Individual	0%	338	$4,000	—	30 Jun 2024	13F
Schond L. Greenway	3/4/5	CFO	— class O/S missing	3,883	$2,017	—	10 Dec 2021	3/4/5
MORGAN STANLEY	13F	Company	0%	10	$124	—	30 Jun 2024	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	4	$50	—	30 Jun 2024	13F
FMR LLC	13F	Company	0%	2	$25	—	30 Jun 2024	13F
GROUP ONE TRADING LLC	13F	Company	0%	2	$25	—	30 Jun 2024	13F
JPMORGAN CHASE & CO	13F	Company	0%	2	$25	—	30 Jun 2024	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	2	$24	—	30 Jun 2024	13F
Activest Wealth Management	13F	Company	0%	1	$12	—	30 Jun 2024	13F
Key FInancial Inc	13F	Company	0%	1	$12	—	30 Jun 2024	13F
Parallel Advisors, LLC	13F	Company	0%	1	$12	—	30 Jun 2024	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	1	$12	—	30 Jun 2024	13F
Stephen Smolinski	3/4/5	Chief Commercial Officer	— class O/S missing	400,000	—	—	04 Jan 2022	3/4/5
Michael F. Cola	3/4/5	Chief Executive Officer, Director	— class O/S missing	78,116	—	—	01 Oct 2021	3/4/5
Sol J. Barer	3/4/5	Director	— class O/S missing	40,000	—	—	15 Jun 2021	3/4/5
Joseph M. Miller	3/4/5	Director	— class O/S missing	20,239	—	—	31 Mar 2022	3/4/5
Suzanne Louise Bruhn	3/4/5	Director	— class O/S missing	5,204	—	—	10 Nov 2021	3/4/5
Phil Gutry	3/4/5	Director	— class O/S missing	4,718	—	—	01 Dec 2021	3/4/5
Magnus Persson	3/4/5	Director	— class O/S missing	3,334	—	—	20 Dec 2023	3/4/5

Institutional Holders of Avalo Therapeutics, Inc. - Common Stock (AVTX) as of Q3 2024

As of 30 Sep 2024, Avalo Therapeutics, Inc. - Common Stock (AVTX) was held by 28 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 6,656,933 shares. The largest 10 holders included Ikarian Capital, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Deep Track Capital, LP, BVF INC/IL, Logos Global Management LP, COMMODORE CAPITAL LP, TCG Crossover Management, LLC, BOOTHBAY FUND MANAGEMENT, LLC, and Sio Capital Management, LLC. This page lists 28 institutional shareholders reporting positions in this security for the Q3 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders

Q3 2024 holders

Holder diff

Investor	Q2 2024 Shares	Q3 2024 Shares	Share Diff	Share Chg %	Q2 2024 Value $	Q3 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.